首页 | 官方网站   微博 | 高级检索  
     


DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer
Affiliation:1. Predictive Oncology Laboratory, Centre de Recherche en Cancérologie de Marseille, Inserm UMR 1068, CNRS UMR 7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Bd. Leï Roure, 13273 Marseille, France;2. Department of Life Science, University of Science and Technology of Hanoi, Hanoi 000084, Vietnam;3. Marseille Protéomique, Centre de Recherche en Cancérologie de Marseille, INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, 13009 Marseille, France;4. Inria – Inserm team COMPO, COMPutational pharmacology and clinical Oncology, Centre Inria Sophia Antipolis – Méditerranée, Centre de Recherches en Cancérologie de Marseille, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, 27 Boulevard Jean Moulin, 13005 Marseille, France;5. Urology Deparment, AP-HM Hospital Nord, Aix-Marseille University, 13915 Marseille Cedex 20, France;6. The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC V6H 3Z6, Canada;7. La Timone University Hospital, Aix-Marseille University, 13005 Marseille, France;8. European Center for Research in Medical Imaging, Aix-Marseille University, 13005 Marseille, France
Abstract:
><ol class=
  • Download : Download high-res image (218KB)
  • Download : Download full-size image
  • Keywords:antisense oligonucleotides (ASOs)  castration-resistant prostate cancer (CRPC)  DDX5  DNA damage response (DDR)  protein interactions  Hsp27  therapeutic ressistance
    本文献已被 ScienceDirect 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

    京公网安备 11010802026262号